Magistro G, Stief C G, Gratzke C
Urologische Klinik und Poliklinik der Universität München, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377, München, Deutschland.
Urologe A. 2016 Nov;55(11):1419-1432. doi: 10.1007/s00120-016-0249-4.
Novel minimally invasive treatment options for the management of male lower urinary tract symptoms (LUTS) due to bladder outlet obstruction (BOO) aim to provide equal efficacy compared to standard techniques with a more favourable safety profile. The preservation of all aspects of male sexual function including antegrade ejaculation is increasingly important to patients. It should be ideally performed in an outpatient setting under local anesthesia to assure a short recovery time. Novel injectables for intraprostatic application (botulinum neurotoxin A, NX-1207, PRX302) have emerged and first phase III results could not confirm the promising initial data. For mechanical devices like Urolift® the early and mid-term benefits demonstrate a rapid and durable symptom relief without compromising sexual function. Novel innovative procedures like aquablation (AquaBeam®) are entering the scene, but their feasibility, efficacy and safety still need to be addressed in randomized controlled trials.
用于治疗因膀胱出口梗阻（BOO）导致的男性下尿路症状（LUTS）的新型微创治疗方案旨在提供与标准技术相当的疗效，同时具有更良好的安全性。对患者而言，保留男性性功能的各个方面，包括顺行射精，变得越来越重要。理想情况下，该治疗应在门诊局部麻醉下进行，以确保恢复时间短。用于前列腺内注射的新型药物（肉毒杆菌神经毒素A、NX - 1207、PRX302）已出现，但其III期初步结果未能证实初期令人期待的数据。对于像Urolift®这样的机械设备，早期和中期疗效表明其能迅速且持久地缓解症状，同时不损害性功能。像水消融术（AquaBeam®）这样的新型创新手术正在出现，但它们的可行性、疗效和安全性仍需在随机对照试验中加以研究。
